Drug Trial Radar · NCT04977453
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
317
Planned (sponsor's estimate)
Start
Aug 2, 2021
Primary completion
Jun 30, 2028
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- GI Innovation, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Jul 27, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab or lenvatinib over a range of advanced and/or metastatic solid tumors.
Conditions
- Advanced Solid Tumor
- Metastatic Solid Tumor
- Cervical Cancer
- Urothelial Carcinoma
- Clear Cell Renal Cell Cancer (ccRCC)
- Squamous Cell Non Small Cell Lung Cancer
Interventions
GI-101Drug
Recommended phase 2 dose of GI-101 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
Pembrolizumab (KEYTRUDA®)Drug
Pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.
LenvatinibDrug
Lenvatinib will be administered at an approved dose orally.
GI-101ADrug
Recommended phase 2 dose of GI-101A will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and nature of Dose-Limiting Toxicity (DLTs), Incidence, nature, and severity of adverse events (AEs) and immune-related AEs (irAEs)Time frame: Study Day 1, assessed up to approximately 24 months
- Objective Response Rate (ORR), Disease Control Rate (DCR) and Duration of Response (DoR) according to RECIST version 1.1Time frame: Study Day 1, assessed up to approximately 24 months
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
Tisch Cancer Institute (TCI), Icahn School of Medicine
New York, New York · Recruiting
Columbia University
New York, New York · Recruiting
Carolina Biooncology Institute
Huntersville, North Carolina · Recruiting
Yonsei University Health System, Severance Hospital
Seoul, South Korea · Recruiting
Yonsei University Health System, Severance Hospital
Seoul, South Korea · Recruiting
Asan Medical Center
Seoul, South Korea · Recruiting
The Catholic University of Korea Seoul ST.MARY'S Hospital
Seoul, Banpo-daero, South Korea · Recruiting
Seoul National University Bundang Hospital
Seoul, Bundang-gu, South Korea · Recruiting
Chungnam National University Hospital
Daejeon, Daejeon, South Korea · Recruiting
Samsung Medical Center
Seoul, Gangnam, South Korea · Recruiting
The Catholic University of Korea St. Vincent's Hospital
Suwon, Kyeonggi-do, South Korea · Recruiting
Korea University Anam Hospital
Seoul, Seongbuk-gu, South Korea · Recruiting
Ewha Womans University Mokdong Hospital
Seoul, Yangcheon-gu, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.